December 2, 2011 Critical Path Institute Gathers Cross-Sector Innovators at Global Conference on Drug Development Hundreds of leaders from cross-sector arenas in government, academia, the biotechnology and pharmaceutical industry, and patient a
November 10, 2011 CPTR Yields Progress: New Five-Way Agreement Among Pharmas and NGOs will Speed Development of TB Drug Combinations The Critical Path to TB Drug Regimens (CPTR) today announced an innovative agreement between AstraZeneca, Sanofi, Tibotec, TB Alli
November 10, 2011 The Patient-Reported Outcome Consortium: Filling Measurement Gaps for PRO End Points to Support Labeling Claims
November 8, 2011 Brian Harvey, VP, U.S. Regulatory Policy at Sanofi, speaks on panel at Partnering for Cures Nov. 8, 2011 Highlights benefits of public-private partnerships like C-Path’s Coalition Against Major Diseases (CAMD): Stresses importanc
November 3, 2011 Capturing the Signal in Mild Cognitive Impairment of the Alzheimer’s Type: Industry Partnerships in Pre-Competitive Measure Development
November 2, 2011 C-Path Joins Leading Voices and Organizations in Alzheimer’s Research, Drug Discovery and Care to Call for Dramatic New Strategy to Stop Alzheimer’s Disease in Report Out Today Leaders Engaged on Alzheimer’s Disease (LEAD) was created in February 2008 as an open network of Alzheimer’s-serving o
October 29, 2011 C-Path’s Avilés Discusses Importance of Data Standards in FDA Week Article FDA is encouraging industry to use newly crafted therapeutic data standards — such as utilization of qualified biomarkers